Drug price hawk CVS Health and the case of the $44,000 nutrition supplement

Carly Helfand CVS Health may be staring down pricey hep C drugs and forthcoming PCSK9 meds, but capsules of powdered resveratrol? Not so much. FiercePharma News

Consumer group demands FDA correct ‘compounded mistake’ on Vanda’s Hetlioz label

Carly Helfand The FDA has already admitted that it made a mistake with its initial approval letter for Vanda Pharmaceuticals' sleep disorder drug early last year, a consumer advocacy ...

Pfizer in quick succession turns aside second lawsuit alleging Zoloft birth defects ties

Eric Palmer Just weeks after winning the first case to go to trial that accused Pfizer of hiding birth defect risks for the children of women who took the antidepressant Zoloft during ...

Mylan expands cancer drug recall on particle contamination worries

Tracy Staton Sterile injectable drugs are notoriously tricky to manufacture. Mylan has found that out the hard way, and it's now expanding a recall of cancer drugs that it began ...

Sanofi and Regeneron’s would-be blockbuster clears FDA hurdle, but questions remain

Damian Garde A cholesterol-slashing treatment from Sanofi and Regeneron won over a key FDA panel, signaling a likely approval but leaving unclear just which patients should get the ...

One of Takeda’s big cancer bets flops in a Phase III lymphoma trial

Damian Garde Alisertib, a jewel of Takeda's $ 8.8 billion acquisition of Millennium Pharmaceuticals back in 2008, failed to make the grade in a Phase III lymphoma trial, forcing ...

‘No path forward’ with Teva, Mylan pledges amid warring roadshows

Carly Helfand Late last month, Teva kicked off a roadshow to meet shareholders of its buyout target, Mylan, and find out what price it'll need to put forth to convince them to support ...

Gilead jumps into epigenetics with a bite-size biotech buyout

Damian Garde As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing ...

J&J, Novartis lead pharma companies by market cap

Carly Helfand Which Big Pharma companies have the biggest market caps in the industry? The Motley Fool has a breakdown of the top 10, but we'll give you a hint: The list ...

Cellectis pulls off a $228M IPO to bankroll its CAR-T ambitions

Damian Garde Cellectis, a French company with a proprietary spin on one of biotech's hottest fields, made an up-sized debut on Wall Street, grossing more than $ 228 million. FierceBiotech ...

Acadia craters as takeover buzz is silenced by (another) NDA delay, CEO exit

John Carroll San Diego-based Acadia Pharmaceuticals put out word on Wednesday evening that it is delaying its expected NDA for pimavanserin from Q1 back to some time in the second half ...

FDA panel backs Kythera’s double chin-fighting shot

Damian Garde Kythera won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment. FierceBiotech News
Page 4 of 34« First...23456...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS